- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.12. | LTR PHARMA LIMITED: Notification regarding unquoted securities - LTP | - | ASX | ||
| 16.12. | LTR PHARMA LIMITED: LTR Pharma Surpasses 1,000 SPONTAN Prescriptions | - | ASX | ||
| 10.12. | LTR PHARMA LIMITED: Application for quotation of securities - LTP | - | ASX | ||
| 09.12. | LTR PHARMA LIMITED: TGA Provides Regulatory Clearance for SPONTAN Phase II | - | ASX | ||
| 02.12. | LTR PHARMA LIMITED: Ethics Approval Received for SPONTAN Phase II Clinical Study | - | ASX | ||
| LTR PHARMA Aktie jetzt für 0€ handeln | |||||
| 02.12. | LTR PHARMA LIMITED: Release of Restricted Securities from ASX Mandatory Escrow | 3 | ASX | ||
| 20.11. | LTR PHARMA LIMITED: Change of Director's Interest Notice - M McGuire | - | ASX | ||
| 20.11. | LTR PHARMA LIMITED: Change of Director's Interest Notice - J Chick | - | ASX | ||
| 20.11. | LTR PHARMA LIMITED: Change of Director's Interest Notice - L Rodne | - | ASX | ||
| 20.11. | LTR PHARMA LIMITED: Notification regarding unquoted securities - LTP | 2 | ASX | ||
| 20.11. | LTR PHARMA LIMITED: Notification regarding unquoted securities - LTP | - | ASX | ||
| 19.11. | LTR PHARMA LIMITED: Application for quotation of securities - LTP | - | ASX | ||
| 18.11. | LTR PHARMA LIMITED: Bell Potter Healthcare conference presentation | - | ASX | ||
| 29.10. | LTR PHARMA LIMITED: Investor Presentation | - | ASX | ||
| 28.10. | LTR PHARMA LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 24.10. | LTR PHARMA LIMITED: Results of Meeting | - | ASX | ||
| 24.10. | LTR PHARMA LIMITED: AGM Presentation | - | ASX | ||
| 23.10. | LTR Pharma - Sizable upside potential for intranasal delivery | 305 | Edison Investment Research | LTR Pharma is a clinical- and commercial-stage pharmaceutical company pioneering intranasal drug delivery with lead product SPONTAN, a first-in-class nasal spray for erectile dysfunction (ED). LTR has... ► Artikel lesen | |
| 06.10. | LTR PHARMA LIMITED: LTR increases LevOmega stake to 43% with $1m investment | 1 | ASX | ||
| 26.09. | LTR PHARMA LIMITED: Application for quotation of securities - LTP | - | ASX |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 37,010 | +1,63 % | Novo Nordisk glänzt mit neuer Zulassung, Bayer erhält in Japan grünes Licht, DroneShield baut Vertrauen auf und TUI beschenkt Anleger mit neuen Höchstständen | An den US-Börsen findet heute noch einmal ein verkürzter Handel statt. Hierzulande haben sich die Märkte derweil in ein langes Weihnachtswochenende verabschiedet. Pünktlich zum Fest gab es dabei in... ► Artikel lesen | |
| MERCK KGAA | 122,60 | +0,62 % | MERCK KGAA: Jetzt kippt der Moment - ich bin alarmiert! | ||
| NOVO NORDISK | 44,025 | +0,01 % | NOVO NORDISK A/S - Stabilität als strategische Basis | ||
| AQUESTIVE THERAPEUTICS | 6,390 | -1,24 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Broadens Patent Estate for Anaphylm | New patents extend protection for Anaphylm into 2037Anaphylm (dibutepinephrine) Sublingual Film, if approved by the FDA, will be the first and only oral medication for the rescue treatment of severe... ► Artikel lesen | |
| HARROW | 50,09 | -1,33 % | Harrow, Inc.: Harrow Health, Inc. Announces Closing of Acquisition of Melt Pharmaceuticals | NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the... ► Artikel lesen | |
| SCHOTT PHARMA | 15,100 | 0,00 % | Schott Pharma: Entwicklung und aktuelle Einschätzung | ||
| PFIZER | 21,255 | -0,12 % | Pfizer (PFE) Braces for Bumpy Years as Growth Pushed Out to 2029 | ||
| LB PHARMACEUTICALS | 21,500 | +0,47 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer | NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for... ► Artikel lesen | |
| DERMAPHARM | 39,350 | +0,38 % | DERMAPHARM HOLDING SE kracht ab - jetzt wird's brutal spannend! | ||
| MILESTONE PHARMACEUTICALS | 1,960 | 0,00 % | Milestone Pharmaceuticals Inc.: Milestone Receives FDA Approval of CARDAMYST (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) | First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythmFDA approval in PSVT enables... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 75,85 | -2,91 % | Cantor Fitzgerald bestätigt "Overweight" für Bright Minds Biosciences und sieht Potenzial in Hauptwirkstoff BMB-101 | ||
| ETON PHARMACEUTICALS | 16,790 | -0,06 % | Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution) | - NDA assigned a Target Action Date of February 25, 2026 -- Product has patent protection through 2044 - DEER PARK, Ill., July 08, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the... ► Artikel lesen | |
| NOVABAY PHARMACEUTICALS | 6,170 | 0,00 % | NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards | EMERYVILLE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that it has regained compliance with the NYSE American's... ► Artikel lesen | |
| ASTRAZENECA | 157,85 | +0,13 % | Jacobio, AstraZeneca ink cancer drug deal | ||
| SANOFI | 83,03 | 0,00 % | Sanofi will US-Impfstoffhersteller Dynavax für 2,2 Milliarden Dollar kaufen | PARIS (dpa-AFX) - Der Pharmakonzern Sanofi will den US-Impfstoffhersteller Dynavax für gut zwei Milliarden Dollar kaufen. Das Gebot liege bei 15,50 US-Dollar je Aktie in bar, teilten die Franzosen... ► Artikel lesen |
Das Unternehmen LTR PHARMA LIMITED kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LTR PHARMA LIMITED finden Sie auf Wallstreet Online.